Trial
NCT07082270
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
—
Condition
Recurrent Multiple Myeloma
Intervention
Biospecimen Collection
Why stopped
Sponsor withdrawal of supplying investigational drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-15